Boston, United States
Manifold Bio, founded in 2020, is a cutting-edge platform therapeutics company headquartered in the United States. The company is known for its bold tagline: "Organism-scale intelligence, designed in vivo". It specializes in leveraging biotechnology, healthcare, health and wellness, and pharmaceuticals to create impactful solutions in the pharmaceutical industry.
The company's distinctive approach is embodied in its mDesign engine, which uniquely integrates AI-guided protein design with multiplexed in vivo data generation. This process enables a continuous cycle of design and translation, ultimately aiming to build a 'virtual organism.' Manifold Bio not only advances its internal pipeline but also collaborates with major global pharmaceutical partners to ensure organism-scale biology has a profound clinical impact.
Recently, Manifold Bio secured a $15.00M Series A investment on April 1, 2024, with contributions from notable investors like SK Ventures, Calibrate Ventures, and TQ Ventures. This investment underscores the growing confidence in Manifold Bio's innovative platform and its potential to revolutionize therapeutic development.
